Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Coli surface antigen 5 (CS5), also known as CS5 fimbrial antigen, is a plasmid-encoded, helical fibrillar adhesin expressed on the surface of enterotoxigenic Escherichia coli (ETEC). It is a key colonization factor that mediates the attachment of ETEC to host small intestinal epithelial cells, a critical initial step in the pathogenesis of ETEC-mediated diarrheal disease. The CS5 operon consists of six genes (csfA-F) encoding the major subunit CsfA, minor subunit CsfD, outer membrane usher CsfC, chaperones CsfB and CsfF, and length regulator CsfE. Expression of CS5 is highly regulated by host environmental cues, particularly requiring the presence of bile salts such as sodium glycocholate in the gut lumen.
In clinical development, CS5 is a major target for multivalent ETEC vaccines aimed at preventing traveler's diarrhea and childhood diarrhea in endemic regions. Vaccines such as ETVAX (an oral inactivated whole-cell vaccine) and ACE527 (a live attenuated vaccine) incorporate CS5-expressing strains or recombinant CS5 antigens to elicit protective mucosal IgA and systemic IgG antibody responses. These antibodies neutralize the adhesin, preventing bacterial colonization and subsequent enterotoxin-mediated fluid secretion. Therapeutic challenges include the high antigenic diversity of ETEC strains and the need to maintain the structural integrity of the fimbriae during vaccine formulation and inactivation.
Active immunization to induce mucosal IgA and systemic IgG antibodies that bind to the CS5 fimbrial antigen, thereby blocking bacterial adhesion and colonization of the small intestinal epithelium by enterotoxigenic Escherichia coli (ETEC).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Coli surface antigen 5 (CS5).